Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in ...

Royalty financing is a relatively new concept that offers an alternative to regular debt financing (loans and trade credit) and equity financing (venture capital and stock sales). In a royalty ...

Tiered royalties adjust rates based on sales, boosting potential profits for high volumes. Smart tiered royalty setups can indicate strong revenue potential in a company. Investors should study ...